Assessing CSL (ASX:CSL) Valuation After RBC Capital Upgrade And Recent Share Price Selloff

Simply Wall St.

Jan 21

RBC Capital’s upgrade of CSL (ASX:CSL) to Outperform after the recent selloff has refocused attention on the stock. Investor interest is building around February’s half year results and the upcoming ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605489670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605489670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605489670?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-01-21 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605489670","market":"us","top_or_hot":-1,"title":"Assessing CSL (ASX:CSL) Valuation After RBC Capital Upgrade And Recent Share Price Selloff","media":"Simply Wall St.","content":"<div>\n<p>RBC Capital’s upgrade of CSL (ASX:CSL) to Outperform after the recent selloff has refocused attention on the stock. Investor interest is building around February’s half year results and the upcoming ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-rbc-capital-upgrade-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CSL (ASX:CSL) Valuation After RBC Capital Upgrade And Recent Share Price Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CSL (ASX:CSL) Valuation After RBC Capital Upgrade And Recent Share Price Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-21 18:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-rbc-capital-upgrade-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RBC Capital’s upgrade of CSL (ASX:CSL) to Outperform after the recent selloff has refocused attention on the stock. Investor interest is building around February’s half year results and the upcoming ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-rbc-capital-upgrade-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-rbc-capital-upgrade-and","article_id":"2605489670","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-rbc-capital-upgrade-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605489670","pubTimestamp":1768991322,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"RBC Capital’s upgrade of CSL (ASX:CSL) to Outperform after the recent selloff has refocused attention on the stock. Investor interest is building around February’s half year results and the upcoming interim dividend decision.\nSee our latest analysis for CSL.\nCSL’s recent selloff has left the share price at A$176.70, with a 90 day share price return of a 19.94% decline and a 1 year total shareholder return of a 34.10% decline, signalling weaker momentum despite the short term lift after the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"在加拿大皇家银行资本升级和近期股价抛售后评估CSL(ASX：CSL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5},"content_text":"RBC Capital’s upgrade of CSL (ASX:CSL) to Outperform after the recent selloff has refocused attention on the stock. Investor interest is building around February’s half year results and the upcoming interim dividend decision. See our latest analysis for CSL. CSL’s recent selloff has left the share price at A$176.70, with a 90 day share price return of a 19.94% decline and a 1 year total shareholder return of a 34.10% decline, signalling weaker momentum despite the short term lift after the RBC Capital upgrade and renewed focus on February’s results. If CSL’s recent volatility has you reassessing healthcare exposure, it could be a good moment to scan other opportunities across healthcare stocks and see what stands out to you. With CSL trading at A$176.70, an indicated 42.50% intrinsic discount and a 32.83% gap to analyst targets, the key question is whether this reflects a genuine opportunity or if the market is already accounting for future growth. AdvertisementPrice to earnings of 19.1x: Is it justified? At A$176.70, CSL is trading on a 19.1x P/E, which appears inexpensive relative to both its own fair ratio and to global biotech peers. The P/E multiple compares the current share price with earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a large, profitable biopharmaceutical group like CSL, it is a commonly used yardstick because earnings are a central focus for many investors. According to Simply Wall St, CSL is considered good value on this measure, with its 19.1x P/E sitting below an estimated fair P/E of 23.8x. This indicates a level the market might move toward if sentiment and earnings expectations remain aligned with that fair ratio framework. The discount is even clearer when you compare CSL’s 19.1x P/E to the peer average of 31.4x and the global biotechs industry average of 27.1x, indicating a materially lower earnings multiple than many similar companies. Explore the SWS fair ratio for CSL Result: Price-to-earnings of 19.1x (UNDERVALUED) However, you still need to weigh risks such as CSL’s 34.10% 1-year total return decline and the possibility that current earnings or margins prove less resilient. Find out about the key risks to this CSL narrative. Another view using our DCF model While the 19.1x P/E paints CSL as inexpensive, our DCF model goes further and values the shares at A$307.32 based on estimated future cash flows, versus the current A$176.70 price. That gap suggests the market could be pricing in a significant amount of execution and growth risk. Look into how the SWS DCF model arrives at its fair value. CSL Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSL for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 872 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own CSL Narrative If you see the data differently or simply want to stress test your own view, you can build a personalised CSL story in just a few minutes using Do it your way. A good starting point is our analysis highlighting 6 key rewards investors are optimistic about regarding CSL. Looking for more investment ideas? Before you move on, give yourself the chance to broaden your watchlist with a few targeted ideas that might suit different parts of your portfolio.  Scan for overlooked value by checking out these 872 undervalued stocks based on cash flows, where you can spot companies that may be priced below their cash flow potential. Tap into powerful long term themes through these 23 AI penny stocks, focusing on businesses tied to artificial intelligence trends. Add income focused names by reviewing these 13 dividend stocks with yields > 3%, which highlights companies offering dividend yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}